New hope for liver transplant patients with recurrent cancer: immunotherapy combo under study

NCT ID NCT06254248

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a combination of two drugs, atezolizumab and bevacizumab, can safely treat liver cancer that has come back after a liver transplant. The study includes 50 patients who will receive the drug combo every three weeks along with a strict immunosuppressive regimen to lower the risk of organ rejection. The main goal is to see how many patients experience acute cellular rejection within six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab-Bevacizumab (immunotherapy plus anti-angiogenic drug) combined with standard immunosuppressants (tacrolimus, mycophenolate mofetil, corticosteroids, and possibly everolimus)
What this could lead to: If this works, it could offer a new treatment option for liver transplant patients whose cancer has returned, potentially controlling the cancer without causing organ rejection.
What could go wrong: This is a small, early-phase trial with only 50 participants, and the immunotherapy may still trigger liver rejection despite the added immunosuppression. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA RECURRENT LIVER TRANSPLANT SYSTEMIC TREATMENT

Contacts and locations

Locations

CHU Montpellier - Hôpital Saint Eloi
RECRUITING

Montpellier, 34295, France
CHU Rennes - Hôpital Pontchaillou
RECRUITING

Rennes, 35033, France
CHU Tours - Hôpital Trousseau
RECRUITING

Tours, 37044, France
Hôpital Beaujon
RECRUITING

Clichy, 92110, France
Hôpital Claude Huriez - CHU de Lille
RECRUITING

Lille, 59037, France
Hôpital Henri-Mondor
RECRUITING

Créteil, 94010, France
Hôpital Paul Brousse
RECRUITING

Villejuif, 94800, France
Hôpital Pitié-Salpêtrière
RECRUITING

Paris, 75013, France
Hôpital de Hautepierre - Strasbourg
RECRUITING

Strasbourg, 67200, France
Lyon - Hôpital Croix Rousse
RECRUITING

Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.